---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-030824"
form_type: "8-K"
ticker: "ANNX"
cik: "0001528115"
company_name: "Annexon, Inc."
filed_at: "2025-03-03T23:59:59+00:00"
generated_at: "2026-05-25T17:35:26.727440+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Annexon reports Q4 2024 net loss $48.6M; cash $312M; key pipeline milestones for GBS and dry AMD

## Summary
- Cash $312.0M as of Dec 31, 2024; runway into 2H 2026.
- Net loss $48.6M Q4 2024 vs $27.9M Q4 2023; R&D expense $43.4M.
- Pre-BLA meeting for GBS drug ANX005 targeted 1H 2025; BLA submission planned.
- Global registration path for ANX007 in dry AMD with GA; Phase 3 ARCHER II data expected 2H 2026.
- ANX1502 oral C1s inhibitor POC trial ongoing; dataset in up to 7 CAD patients expected mid-2025.

## SEC filing metadata
- accession: 0000950170-25-030824
- form_type: 8-K
- ticker: ANNX
- cik: 0001528115
- company_name: Annexon, Inc.
- filed_at: 2025-03-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1528115/000095017025030824/0000950170-25-030824-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1528115/000095017025030824/annx-20250303.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-030824
- JSON: https://secwatch.observer/filing/0000950170-25-030824.json
- Plain text: https://secwatch.observer/filing/0000950170-25-030824.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.